Anti-Human CD2 (LO-CD2a) - Purified in vivo GOLDTM Functional Grade
| Code | Size | Price |
|---|
| LEI-C509-1.0mg | 1.0 mg | £175.00 |
Quantity:
| LEI-C509-5.0mg | 5.0 mg | £380.00 |
Quantity:
| LEI-C509-25mg | 25 mg | £1,014.00 |
Quantity:
| LEI-C509-50mg | 50 mg | £1,556.00 |
Quantity:
| LEI-C509-100mg | 100 mg | £2,159.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rat
Antibody Isotype: Rat IgG2b κ
Antibody Clonality: Monoclonal
Antibody Clone: LO-CD2a
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Flow Cytometry
- Functional Study
- In Vivo Assay
Shipping:
2 - 8°C Wet Ice
Storage:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.
Further Information
Antigen Distribution:
CD2 is expressed on all mature human T cells, most thymocytes, NK cells and a small proportion of bone marrow cells.
Concentration:
? 5.0 mg/ml
Conjugate/Tag/Label:
in vivo GOLD™, Purified in vivo Functional Grade
Format:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
Purified human T Lymphocytes
Long Description:
Human CD2 is a 351 amino acid transmembrane glycoprotein that is part of the immunoglobulin superfamily1, 2. CD2 is expressed on the surface of mature T cells, most NK cells, thymocytes, dendritic cells, and 9-12% of bone marrow cells. CD2 participates in T cell and NK cell activation and is important for thymocyte development and assembly of the immunological synapse1. However, the role of CD2 in murine immunity is not always consistent with its function in higher animals. CD2 is known to bind to lymphocyte-associated antigen3 (CD58 and its murine analog CD48) as well as CD59. LO-CD2a was developed as an immunosuppressive agent for use in organ allotransplantation3, 4. LO-CD2a strongly inhibits mixed lymphocyte culture3 and induces T cell apoptosis5. Additionally, LO-CD2a induces very low levels of cytokine release, inhibits cytokine production induced by OKT3, and induces human T cell hyporesponsiveness3. The immune response is inhibited as a result of cell lysis by antibody-dependent cell mediated cytotoxicity (ADCC) induced by NK cells and activated monocytes and from CD2 down-modulation on CD2+ cells6. LO-CD2a also strongly inhibits proliferation of peripheral blood mononuclear cells stimulated with soluble OKT3. LO-CD2a has demonstrated immunosuppressive activity in vitro and effective T cell depletion in vivo. Unresponsiveness upon restimulation with the same antigen makes LO-CD2 distinct from other anti-CD2 antibodies7.
NCBI Gene:
914
Purity:
?95% monomer by analytical SEC, >95% by SDS Page
Target:
CD2
References
1. Binder C, Cvetkovski F, Sellberg F, et al. Front Immunol. 11:1090. 2020. 2. Bierer BE, Sleckman BP, Ratnofsky SE, et al. Annu Rev Immunol. 7:579?599. 1989. 3. Latinne D, De La Parra B, Nizet Y, et al. Int Immunol. 8(7):1113-1119. 1996. 4. Bazin H, Latinne D, et al, inventors; Biotransplant Inc, assignee. LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation. US patent 6,849,258 B1. Feb 1, 2005. 5. Dumont C, D?as O, Mollereau B, et al. J Immunol. 160(8):3797-3804. 1998. 6. Nizet Y, Chentoufi AA, de la Parra B, et al. Transplantation. 69(7):1420-1428. 2000. 7. Xu Y, Kolber-Simonds D, Hope JA, et al. Clin Exp Immunol. 138(3):476-483. 2004.